Serenity 持仓雷达 › 个股索引 › $NVO
$NVO · 海外大V持仓追踪
AI 把海外大 V 的公开帖整理成中文：$NVO 被累计提及 30 次，本周态度 未表态，医疗健康。数据每日更新。
$NVO 现在是什么情况？
| 所属板块 | 医疗健康 |
|---|---|
| 本周态度 | 未表态 |
| 今日态度 | 未表态 |
| 累计提及 | 30 次 |
| 近7/28/90日提及 | 0 / 0 / 0 |
| 最新价 | USD 48.76（2026-07-14） |
| 今日 / 本周涨幅 | -1.1% / -1.8% |
| 首次提及以来涨幅 | -13.5% |
| 首次 / 最近提及 | 2025-08-23 → 2026-05-09 |
最近有人说了 $NVO 什么？
下面是最近 8 条提及 $NVO 的公开帖，按时间倒序。每条都附原帖链接，可自行核对。
- 2026-05-09中性原文I feel like all the $FISV, $PYPL, $NVO value/dividend investors went extinct this cycle? Was very popular, even last year… But if you pivoted to semis like $INTC or $SNDK, you would be up 200-400%+ YTD. X feed is just AI bottlenecks now, feel like I helped start a new trend? https://t.co/tj7ykBGMyr
- 2026-04-17中性原文It’s still pretty incredible $HIMS is down 44% even after: 1. $NVO de-risking + partnership 2. Multiple global acquisitions expanding DTC distribution network 3. Peptide arc, with Huberman saying HIMS was set to soar under these conditions 4. Entering a friendlier macro climate. 5. Short interest reaching unsustainable 36%+ The good news is: short interest can only be so much of the float… So it’s inherent buying pressure to cover over time, which does limit downside if fundamentals improves.
- 2026-04-15中性原文This announcement is the most bullish catalyst for $HIMS revenue re-acceleration to date. This is amid: - 30%+ of the float sold short - new $NVO partnership/lawsuit dropped - new global acquisitions - recovering macro climate. The share price is still $25, down from $70 last year. Short sellers are likely in trouble: $HIMS can capture market share at the ~70%-80% gross margins typical of their compounded products for the holy grail of the "Grey Market" TAM for peptides. - EG. Healing: BPC-157 and Thymosin beta-4 - Hair & Skin: GHK-Cu - Weight Loss & Muscle: MOTS-c and Ibutamoren And now they're probably the world's largest independent DTC distribution network to date from their new acquisitions... So just running a peptide protocol subscription between $150 to $300, for 200k subscribers is $360M+ in high-margin ARR. As just one example, but now they have a worldwide net of customers. They burned through capex last year to acquire peptide manufacturing facilities too... so now that's turned into a massive cash-cow business. I said $HIMS would need fundamental changes in order to force shorts to cover, and this is probably that signal as seen with market data. And $HIMS is turning into a fundamentally sound company after regulatory de-risking.
- 2026-03-12看空原文@alc2022 Makes sense though given $NVO dropping the lawsuit and partnering with $HIMS was a surprise to majority of people. Definitely caught a lot of people off guard, especially short sellers that didn’t cover and thought $HIMS was going under
- 2026-03-11中性原文$HIMS is now back up 14.22%. The untapped latent revenue from their their global DTC retail distribution moat is extreme. And draws parallels to the early acquisitions from $META. As well as the cross-selling capabilities of $HOOD. $HIMS is still down from it's $70+ highs, after acquiring three major global competitors without regulatory friction. And best of yet: Shorts that sold 40%+ of the company short directionally, are completely trapped from the surprising $NVO partnership + lawsuit termination. I would personally hold and go long here on HIMS. The risk/reward on management effectively monetizing that massive, global retail distribution network for healthcare seems worth it.
- 2026-03-11中性原文I try to talk about $HIMS from a fundamental standpoint. But this cannot be understated: $HIMS directional shorts look trapped. The stock price is now up 64.15% to $26.5 (still down from highs of $70s). While short interest increased to record highs of 41.6%. There may be a violent feedback loop as short positions go more underwater. However; this is contingent on the underlying stock going up from buying pressure and increasing fundamentals. In order for their positions get liquidated. Otherwise, if prices stagnates, they can leave their short sales in for extended periods of time (low borrow rate) and slowly buy to cover. That being said, I'm personally along for the ride and looking forward to seeing what $HIMS can deliver: Both from their recent $META-like global acquisitions spree + $HOOD-like cross selling latent revenue opportunities. With $HIMS rapidly improving fundamentals, from the surprise $NVO partnership: I personally see a real opportunity for $HIMS to make history.
- 2026-03-10中性原文Does nobody else see the parallels to $HIMS and $META and $HOOD? $HIMS literally just bought out the largest players around the world: - Zava (Europe/UK) - Livewell (Canada) - Eucalyptus (Australia/Japan) Without antitrust blocking it? $META did that a decade ago with companies like WhatsApp and Instagram with minimal friction. Now no social media company anymore can go on buying sprees due to regulator PTSD after $META ended up a trillion dollar monopoly. $HIMS now is the largest independent global retail DTC distribution network in the world, after their M&A spree. And just needs to figure out how to cross-sell products like what $HOOD did for financial products? $HOOD previously had the SEC + Gary trying to block all their crypto offerings. But ever since they got regulatory headaches cleared up, they managed to scale to become a $70B company off cross-selling fintech products to their retail audience. I'm seeing strong parallels to $NVO / Regulators trying to block $HIMS product offerings. However, that regulatory uncertainty is now cleared up after $NVO partnered with $HIMS and FDA dropped their threats. The potential is there? I can't be the only one who sees potential from $HIMS global DTC retail distribution network and latent revenue monetization?
- 2026-03-09看空原文$HIMS overnight trading will begin soon after finishing Friday at $22. Previously it traded at $70, but given: - $NVO / US Gov lawsuit threatening to bankrupt the company - $HIMS revenue deceleration from GLP-1. Short sellers shorted 40%+ of the company’s float. All of that flipped Friday after hours once $NVO partnered up with $HIMS per Bloomberg, in an extremely surprising event. Due to revenue reaccelerating, new acquisitions for global expansion, no threats of balance sheet insolvency, and now a partnership with $NVO: Short sellers now face infinite losses, selling close to half of the float short. And the setup looks prime for a short squeeze. However, the outcome primarily depends on how retail reacts or if they capitulate to short sellers. Either way, everyone will be watching Monday to see whether $HIMS cactus pills serves as a macroeconomic flight to safety against crude oil.
去哪看 $NVO 的完整时间线？
全部提及推文的中文时间线、每日推演、博主多空表态筛选，在 Serenity 持仓雷达里查看。相关工具：卡点猎手研究方法 · 策略回测器 · 催化剂雷达 · 深度长文。
进入持仓雷达，看 $NVO 完整动态 →常见问题
$NVO 为什么会出现在 AI 供应链追踪名单里？
$NVO 出现在 Serenity 持仓雷达里，是因为它被我们追踪的海外 AI 供应链博主公开提及过，累计 30 次，归类在「医疗健康」板块。首次提及时间是 2025-08-23。
海外大 V 最近怎么看 $NVO？
最近 7 天 $NVO 被提及 0 次，本周的整体态度是「未表态」。这是对公开帖文的统计与翻译，不是我们自己的推荐。
$NVO 从被提及到现在涨了多少？
从首次被提及（2025-08-23）到最新收盘，$NVO 的区间涨幅是 -13.5%。这只是价格统计，不代表任何人的实际收益。
$NVO 这一页的数据多久更新一次？
每天更新一次。个股的提及次数、态度、涨幅、A 股映射都跟着当日的公开帖文和收盘价重算，页面底部的更新时间就是最后一次重建的日期。
Serenity 持仓雷达对 $NVO 的看法算投资建议吗？
不是。Serenity 持仓雷达只做公开信息的整理、翻译和统计，不提供投资建议、不代客理财、不推荐买卖。所有判断和后果由你自己承担。
本工具仅做公开信息整理，不构成任何投资建议。数据更新于 2026-08-30。